Benefits
Menopausal symptom relief — modest
Royal jelly at 800 to 1,000 mg/day for 8 to 12 weeks lowers menopausal symptom scores in postmenopausal women, most clearly for anxiety and low back pain. Read the two trials carefully. The larger one (200 Iranian women, 1,000 mg/day, 8 weeks) reports that scores fell significantly within the royal jelly group and not within the placebo group, which is not the same thing as a significant difference between the groups. The smaller one (42 Japanese women, 800 mg/day of enzyme-treated royal jelly, 12 weeks) did compare the groups directly and found significance on two scores, anxiety (p=0.046) and backache and low back pain (p=0.040), but five of its six authors are employees of the royal jelly company that supplied the product and the sixth was paid an advisory fee by it. A 2026 meta-analysis in Menopause pooled only 2 of its 6 included trials (312 of 471 women) for a standardised mean difference of 0.73 (95% CI 0.50 to 0.96), graded moderate quality. Reasonable consideration for women looking for botanical menopause support, particularly for the mood and physical-symptom aspects. Not a substitute for HRT in severe vasomotor disease.
Mood support during menopause
Some trials report improvements in anxiety, mood, and quality of life with royal jelly supplementation — most relevant for menopausal women experiencing perimenopausal mood changes. Effect sizes are small to moderate, and trial quality varies. Reasonable adjunct for mild mood symptoms in the menopausal transition. Don't choose royal jelly specifically for clinical depression — saffron, EPA-rich omega-3, and SSRIs all have stronger evidence for mood disorders.
Possible modest lipid effects
Two small controlled trials report reductions in total cholesterol and LDL. In 40 adults with mild hypercholesterolaemia taking about 3.15 g/day for 3 months, total cholesterol fell from 207 to 183 mg/dL and LDL from 126 to 120 mg/dL, reported as change from baseline within the royal jelly arm rather than as a comparison against placebo. In a second study, 7 of 15 volunteers took 6 g/day for 4 weeks and their total cholesterol and LDL fell significantly against the control group. HDL did not change in either study, and both used doses several times larger than a typical royal jelly capsule. Not validated as a lipid-lowering intervention. If lipid management is the priority, oat beta-glucan, plant sterols, or red yeast rice all have substantially stronger evidence than royal jelly.
Fertility: no human trial evidence for oral royal jelly
Royal jelly has a long history as a folk tonic and fertility aid, and it changes reproductive measures in rodents and livestock. That is where the evidence stops. A PubMed search for royal jelly restricted to randomized controlled trials returns 29 records, and the reproduction studies among them are in ewes, laying hens and broiler chicks; no human trial in that set measured a fertility outcome from a royal jelly product you swallow. The one human fertility study is a crossover study in 99 Egyptian couples with asthenozoospermia (2008) that applied a honey and royal jelly mixture intravaginally around ovulation, which is neither an oral supplement nor royal jelly on its own. Beyond that there is a single 2026 case report of one woman with diminished ovarian reserve who conceived after taking royal jelly proteins, and its authors call it non-generalisable. Do not buy royal jelly for fertility.
Skin health — limited evidence
Royal jelly is included in many topical and oral skincare products, with marketing claims around anti-aging and skin appearance. 10-HDA shows effects on skin cells in the laboratory. The human trials that exist are mostly of royal jelly applied to the face, not swallowed, and topical results do not tell you what a capsule does. Restricting a PubMed search of royal jelly to randomized controlled trials returns 29 records, and the only oral skin study among them is a two-page double-blind placebo-controlled report on skin barrier function in the European Journal of Dermatology (2018), for which no results abstract is indexed. That is the whole oral evidence base for skin. Most skin claims for royal jelly outpace the actual evidence base substantially.
Allergy risk — important safety note
Royal jelly can trigger severe allergic reactions, including anaphylaxis, in people with bee or pollen allergies. Asthma exacerbation has also been reported. Test cautiously and avoid entirely if you have known bee product or pollen allergies. This is an important practical limitation that often gets underplayed in royal jelly marketing — the safety profile isn't as benign as the 'natural superfood' framing implies.
Mechanism of action
Mild Estrogenic Activity
Some royal jelly components show weak estrogenic activity in vitro, potentially binding estrogen receptors at low affinity. This may underlie the menopausal symptom benefits — though effects are far weaker than estrogens or even traditional phytoestrogens (genistein, daidzein).
10-Hydroxy-2-Decenoic Acid (10-HDA) Bioactivity
10-HDA is a unique fatty acid found only in royal jelly. It shows multiple biological activities in vitro: antibacterial, anti-inflammatory, immunomodulatory, and weak estrogen receptor binding. It is the standard quality marker for royal jelly, and ISO 12824:2016 sets a minimum of 1.4 g of 10-HDA per 100 g of fresh royal jelly and 3.5 g per 100 g of freeze-dried royal jelly. Whether the jar in front of you meets that is a separate question: most royal jelly capsules carry no 10-HDA figure on the label, and of the trials cited here only the 800 mg/day Japanese trial reported the 10-HDA content of its product (at least 3.5% 10-HDA and 0.6% 10-HDAA). A product with no stated 10-HDA cannot promise it matches what was tested.
Major Royal Jelly Proteins (MRJPs)
MRJPs (especially MRJP1, also called royalactin) constitute ~80% of royal jelly proteins. They have antimicrobial, antioxidant, and immune-modulating activities in vitro. MRJP3 is also a major allergen — implicated in cross-reactivity with honeycomb in anaphylaxis cases.
Antioxidant Activity
Royal jelly contains phenolic compounds, flavonoids, and unique fatty acids with antioxidant activity. Some clinical trials show modest reductions in oxidative stress markers.
Immunomodulatory Effects
Royal jelly modulates cytokine profiles in vitro — generally toward an anti-inflammatory pattern. The clinical relevance for autoimmune conditions or general immune health is not well-established.
Clinical trials
Double-blind, randomized, placebo-controlled trial. 1,000 mg royal jelly capsules daily or placebo for 8 weeks in postmenopausal women aged 45-60 in Bandar Abbas, Iran. Conducted June to November 2018. (Sharif SN, Darsareh F. Complement Ther Clin Pract 2019;37:47-50. PMID 31470366)
200 postmenopausal women aged 45-60.
Mean baseline menopausal score did not differ between groups. After 8 weeks, the menopausal symptom score reduced significantly in the royal jelly group whereas reduction was not significant in the placebo group. Authors concluded daily 1,000 mg royal jelly was effective for alleviating menopausal symptoms and that further research is necessary to confirm the effect. Note what is reported and what is not: the result is given as a significant fall within the royal jelly group and a non-significant fall within the placebo group, which is not the same as a significant royal jelly versus placebo difference, and no such between-group figure is given.
Double-blind, randomized, placebo-controlled trial. 800 mg/day enzyme-treated royal jelly powder vs. placebo (800 mg dextrin) for 12 weeks. Menopausal symptoms assessed every 4 weeks via Japanese-women-specific questionnaire. The test product was protease-digested lyophilised royal jelly standardised to at least 3.5% 10-HDA and 0.6% 10-HDAA. (Asama T, Matsuzaki H, Fukushima S, Tatefuji T, Hashimoto K, Takeda T. Evid Based Complement Alternat Med 2018;2018:4868412. PMID 29853955)
42 healthy Japanese postmenopausal women (21 per arm). 12-week intervention.
Significant differences in anxiety score (p=0.046) and backache/low back pain score (p=0.040) between RJ and placebo at 12 weeks. No significant differences at 4 weeks. No side effects were observed. Who ran it matters here: five of the six authors are employees of Yamada Bee Company, a royal jelly producer that supplied the test product, and the sixth received a medical advisory fee from the same company. No independent group has replicated this product. Important: Japanese menopausal symptoms differ from Western patterns (more neck stiffness/back pain, fewer hot flashes) — may explain the specific symptom domain effects.
Evidence review and pooled analysis of randomized controlled trials evaluating royal jelly for management of postmenopausal symptoms. This is a pooled analysis of other researchers' trials, not a new trial in people. (Ferraz SD, Stangherlin L, Colonetti T, Rodrigues Uggioni ML, Specht Taschetto I, Ceretta L, Grande AJ, Rosa MID. Menopause 2026;33(4):501-509. PMID 41401249)
6 clinical trials, 471 postmenopausal women (from 281 studies identified).
Royal jelly supplementation significantly improved postmenopausal symptoms vs. placebo. The pooled standardised mean difference of 0.73 (95% CI 0.50 to 0.96, p<0.00001, I-squared 0%, moderate-quality evidence by GRADE) comes from only 2 of the 6 included studies, covering 312 of the 471 women. The other 4 studies were included in the review but were not pooled into that estimate. Authors concluded RJ may offer a promising nonhormone option for managing menopausal symptoms, particularly for women who cannot use hormone therapy. Databases searched through May 2025 (MEDLINE, LILACS, Embase, Cochrane Library); the included studies were published between 2011 and 2021. The authors reported no conflicts of interest.
Case series and immunologic investigation of seven subjects with asthma and/or anaphylaxis following royal jelly ingestion. Skin-prick tests, IgE immunoassays, and protein blotting performed. This is a harms report, not efficacy evidence. It comes from the same Alfred Hospital group in Melbourne as the 1995 report below and continues the same line of work, so the two should be read as one series rather than as two independent confirmations. (Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Clin Exp Allergy 1996;26(2):216-222. PMID 8835130)
7 subjects who developed asthma and (in some cases) anaphylaxis after royal jelly ingestion. 6 of 7 female; all atopic with positive grass pollen reactions. Three of seven also tested with bee venom — negative reactions.
Skin-prick tests, immunoassays, and protein blotting confirmed IgE-mediated true hypersensitivity reactions. 18 different IgE-binding components detected on royal jelly protein blots; one ~55 kDa component bound by all reactive sera. Notably, 38% of bee-venom-allergic subjects (out of 63 sera tested) and 52% of subjects with inhalant/food allergies (out of 75 sera) showed IgE reactivity to royal jelly proteins — suggesting cross-reactivity with common environmental allergens. The authors add two caveats: there was no direct relationship between IgE reactivity to bee venom allergens and to royal jelly proteins, and the clinical meaning of the antibodies found in the control sera is unknown. Separately, a fatal case of royal jelly induced asthma was reported in the Medical Journal of Australia in 1994 (Bullock RJ, Rohan A, Straatmans JA, 160(1):44, PMID 8271989), which is why this is not a minor tolerability footnote.
Original report of royal jelly induced asthma and anaphylaxis, with clinical characteristics and immunologic correlations. This is a harms report, not efficacy evidence, and it comes from the same Alfred Hospital group in Melbourne as the 1996 report above rather than being an independent confirmation of it. (Leung R, Thien FC, Baldo B, Czarny D. J Allergy Clin Immunol 1995;96(6 Pt 1):1004-1007. PMID 8543734)
5 atopic patients with reactions to royal jelly.
Documents IgE-mediated hypersensitivity reactions to royal jelly in atopic individuals. Together with the 1996 immunologic follow-up from the same group, this is the report that established royal jelly as a recognised cause of anaphylaxis. Cross-reactivity with other inhalant allergens may explain why a reaction can happen on a first ingestion.